Case series: Amantadine open-label treatment of impulsive and aggressive behavior in hospitalized children with developmental disabilities

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 40, Issue 6, 2001, Pages 654-657

  King, Bryan H ^a,c   Mark Wright, D ^b   Snape, Michael ^b   Dourish, Colin T ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Vernalis PLC   (United Kingdom)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Aggression; Hyperactivity; Impulsivity; N methyl D aspartate (NMDA)

Indexed keywords

AMANTADINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

AGGRESSION; ARTICLE; CHILD; CLINICAL ARTICLE; DEVELOPMENTAL DISORDER; DOPAMINERGIC SYSTEM; DRUG TOLERABILITY; HUMAN; HYPERACTIVITY; IMPULSIVENESS; INFLUENZA; MALE; PRIORITY JOURNAL; SLEEP DISORDER; STEREOTYPY; VERTIGO;

EID: 14344274335     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-200106000-00009     Document Type: Article

References (14)

1. American Academy of Pediatrics, Committee on Infectious Diseases (1991), Influenza. In: Report of the Committee on Infectious Diseases, 22nd ed. Elk Grove Village, IL: American Academy of Pediatrics, pp 274-281
2. Farnebo LO, Fuxe K, Goldstein M et al. (1971), Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease. Eur J Pharmacol 16:27-38
3. Fugate LP, Spacek LA, Kresty LA, Levy CE, Johnson JC, Mysiw WJ (1997), Measurement and treatment of agitation following traumatic brain injury, II: a survey of the brain injury special interest group of the American Academy of Physical Medicine and Rehabilitation. Arch Phys Med Rehabil 78:924-928
4. Glezen WP (1993), Indications for amantadine in otherwise healthy children. Pediatr Infect Dis J 12:106
5. Gualtieri T, Chandler M, Coons TB, Brown LT (1989), Amantadine: a new clinical profile for traumatic brain injury. Clin Neuropharmacol 12:258-270
6. King BH, Au D, Poland RE (1995), Pretreatment with MK801 inhibits pemoline-induced self-biting behavior in pre-pubertal rats. Dev Neurosci 17:47-52
7. Kornhuber J, Weller M, Schoppmeyer K, Riederer P (1994), Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 43:91-104
8. Masters KJ (1997), Alternative medications for ADHD (letter). J Am Acad Child Adolesc Psychiatry 36:301-302
9. Mattes J (1980), A pilot trial of amantadine in hyperactive children. Psychopharmacol Bull 16:67-69
10. Physicians' Desk Reference (1999), Oradell, NJ: Medical Economics Company, pp 986-989
11. Shields WD, Lake JL, Chugani HT (1985), Amantadine in the treatment of refractory epilepsy in childhood: an open trial in 10 patients. Neurology 35:579-581
12. Stoof JC, Booij J, Drukarch B (1992), Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? Clin Neurol Neurosurg 94(suppl):S4-S6
13. Wenk GL, Danysz W, Mobley SL (1995), MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmacol 293:267-270
14. Wright PF, Khaw KT, Oxman MN, Shwachman H (1976), Evaluation of the safety of amantadine HCl and the role of respiratory viral infections in children with cystic fibrosis. J Infect Dis 134:144-149